Search | Clinical Trials Finder

Conditions: Tumors
Interventions: Rubitecan; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC)
Interventions: EXS74539; Drug
Lead sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Los Angeles, California • Fort Worth, Texas • West Valley City, Utah

Conditions: Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors
Interventions: CDX-585; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Celebration, Florida • New York, New York + 1 more

Conditions: Pain, Anxiety
Interventions: Self-hypnotic relaxation; Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 17
States / cities: Duarte, California • Sacramento, California • South Pasadena, California + 13 more

Conditions: Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma, Bone Tumor, Portal Vein Embolization
Interventions: GPX® Embolic Device; Device
Lead sponsor: Fluidx Medical Technology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 15
States / cities: La Jolla, California • Aurora, Colorado • Chicago, Illinois + 11 more

Conditions: Liver Transplant; Complications
Interventions: Prehabilitation intervention, Caregiver intervention; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 74 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Sinusoidal Obstruction Syndrome, Veno-occlusive Disease, Bone Marrow Transplant Complications
Interventions: Defibrotide; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Cancer, Cardiac Disease, Pulmonary Disease, Neuro-Degenerative Disease, Renal Disease, Stroke, Sepsis, Hepatic Disease
Interventions: Active Intervention, Usual Care; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 55 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Alexander City, Alabama • Meridian, Mississippi • Picayune, Mississippi + 1 more

Conditions: Hepato/Renal Fibrocystic Disease, Autosomal Recessive Polycystic Kidney Disease, Joubert Syndrome, Bardet Biedl Syndrome, Meckel-Gruber Syndrome, Congenital Hepatic Fibrosis, Caroli Syndrome, Oro-Facial-Digital Syndrome Type I, Nephronophthisis, Glomerulocystic Kidney Disease
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2030
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Boston, Massachusetts + 3 more

Conditions: Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions: Sporanox, Diclofenac Sodium; Drug
Lead sponsor: Javelin Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions: Essential Amino Acid (EAA) Supplement, Placebo; Dietary Supplement · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetic Kidney Disease
Interventions: Selonsertib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 5
States / cities: Denver, Colorado • Miami, Florida • Orlando, Florida + 2 more

Conditions: BRAF Gene Mutation, Hepatic Complication, Renal Failure, Solid Neoplasm
Interventions: Dabrafenib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 14 more

Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
Interventions: Azacitidine, Pevonedistat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
Interventions: Byetta 5Mcg Pen Injection; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Portal Hypertension, TIPS
Interventions: BD Liverty™ TIPS Stent Graft; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 17
States / cities: Palo Alto, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 12 more

Conditions: Multiple Organ Failure, End Stage Cardiac Failure, End Stage Chronic Obstructive Airways Disease, Chronic Kidney Disease Stage 5, Hepatic Encephalopathy, Sepsis, Dementia, Multiple Sclerosis, Parkinson's Disease, In-Hospital Cardiac Arrest, Solid Organ Cancer
Interventions: Early order of palliative care consultation; Other
Lead sponsor: Wayne State University; Other
Eligibility: 65 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: End-stage Liver Disease, Renal Insufficiency, Renal Failure
Interventions: mycophenolate mofetil, placebo medication; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 16 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer, Squamous Cell Carcinoma, Head and Neck Cancer, Hepatic Carcinoma, Renal Cell Carcinoma
Interventions: [F-18] VM4-037; Drug
Lead sponsor: Siemens Molecular Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bone Marrow Transplant Complications, Sinusoidal Obstruction Syndrome, Veno Occlusive Disease, Hepatic, Stem Cell Transplant Complications
Interventions: Ultrasound Elastography; Diagnostic Test
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 1 Month to 99 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: San Francisco, California • Boston, Massachusetts • Kansas City, Missouri + 4 more

Conditions: Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease, Interstitial Lung Disease, Amyotrophic Lateral Sclerosis, End Stage Liver Disease, End Stage Renal Disease, Diabetes Complications
Interventions: Respecting Choices First Steps, Five Wishes Form; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Birmingham, Alabama • Atlanta, Georgia • Columbia, South Carolina + 1 more

Conditions: Insulin Resistance, Hypertriglyceridemia, Diabetes, Hepatic Steatosis
Interventions: low-fat diet ( Still recruiting ), Diet; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 14 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

A Study of CDX-585 in Patients With Advanced Malignancies

Nonpharmacologic Analgesia for Invasive Procedures

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

Evaluation of a Simple-Prep Controlled Embolic

Identifying Perceived Barriers and Facilitators Toward a Liver Transplantation Prehabilitation

5-day Defibrotide Treatment for Hepatic SOS/VOD

A Culturally-Based Palliative Care Tele-consult Program for Rural Southern Elders

ARPKD Database Study

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS

Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

Liver and Fat Regulation in Overweight Adolescent Girls

The BD Liverty™ TIPS Stent Graft Study

Timing of Acute Palliative Care Consultation in Critically Ill Patients

Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation

An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037

Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome

Reducing Disparities in the Quality of Advance Care Planning for Older Adults

Novel Therapies for Metabolic Complications of Lipodystrophies